
Sign up to save your podcasts
Or


In this ViVE conference bonus episode of Beyond Longevity, recorded live at the ViVE event in Los Angeles, the conversation explores how BioAro is seeking to bring different strands of personalised health data together within a single longevity platform.
Brock Hay explains BioAro’s approach to integrating genomics, microbiome testing, biomarker analysis, AI-driven interpretation, and personalized supplementation. The central idea is that health and longevity cannot be understood through any single test alone, but require a broader and more connected picture of the individual.
The conversation also examines one of the most important questions in modern health technology, namely data privacy. As more companies collect deeply personal biological information, the focus turns to who owns that data, how it is stored, and whether individuals truly remain in control of how it is used.
The episode also explores how tools such as telomere testing, methylation analysis, gut microbiome testing, and athlete-focused genomics are being positioned within the wider move towards preventive health. It also considers how far today’s longevity interventions can genuinely take us, and where the limits of current science and commercial promise still remain.
Links:
https://bioaro.com/
linkedin.com/in/brock-hay-95204471
00:00 Welcome to Beyond Longevity
02:11 Meet Bio Arrow at ViVE
02:23 All in One Longevity Platform
05:02 Genomics Explained Simply
07:03 Privacy and Data Security
09:13 Genes as Prevention Tools
11:23 Methylation and Telomeres
12:08 Who It’s For and Pricing
16:13 Key Longevity Biomarker
17:40 Telomeres and Supplements
22:13 Future of Personalized Medicine
24:10 Gut Microbiome Testing
28:43 Founder Story and Integration
32:38 Research vs Consent
37:06 Vatra Decentralized Storage
38:58 Rapid Fire Longevity Tips
41:06 Closing Takeaways
On Beyond Longevity, Corinne Briaud Manon discusses women’s healthspan through the lenses of science, consumer trust and commercial execution, drawing on her experience in major corporates and her work across Green Marlin, which advises health and longevity startups, and LongHER, a women’s healthspan community platform.
She explains how the two initiatives connect, including how startups can test their propositions with real consumers, and outlines common early-stage pitfalls such as focusing too much on technical detail and not enough on real consumer need, lacking competitive awareness and structure, and letting passion override business discipline.
The conversation explores what “science-backed” should really mean, why longevity is currently a kind of wild west with real credibility risks, and why women’s health needs to become a serious business if it is to address historic underinvestment.
Corinne emphasises the importance of getting the basics right first for women, including basic health assessments, body composition, sleep, movement, strength and social connection, rather than spending blindly on superficial solutions. She also points out that access remains skewed towards the privileged and that prevention will need to be properly incentivised if it is to reach the masses.
Instagram: @longher_collective
https://www.linkedin.com/in/corinne-briaud-manon/
00:00 Welcome and Guest Intro
01:38 Two Ventures Overview
02:43 Ecosystem Linking Both
04:17 How Longher Helps Startups
06:20 Green Marlin Origin Story
07:39 Startup Gaps and Fixes
11:48 Passion Versus Business
13:00 Spotting Real Innovation
14:44 Authenticity in Longevity Clinics
16:53 From Lab to Market
18:53 What Science Backed Means
20:56 Longevity Wild West
24:09 Why Womens Health Must Scale
28:01 Workplace Healthspan Shift
28:30 Workplace Health Costs
29:19 Menopause Support Programs
30:57 Women Led Health Startups
32:09 Beauty Versus Longevity Hype
33:54 Muscle Health Foundations
35:29 Where To Begin Basics
39:17 Stop Wasting On Superficial
41:14 Longevity Access Inequality
45:19 Prevention Model Shift
50:02 Future Of Longevity Trust
51:49 Rapid Fire Takeaways
55:32 Closing Reflections
Professor Lorna Harries has spent more than two decades studying why cells age and what might be done about it. In this episode, she explains one of the most overlooked mechanisms in ageing biology, RNA splicing. When cells lose control of this process, they become stressed, dysfunctional and can tip into senescence, a state that contributes to ageing across almost every organ system.
She explains what senescent cells actually do, how the signals they release can spread damage from one tissue to another, and why calling them “zombie cells” does not come close to telling the full story. We talk about the possibility of intervening before cells reach an irreversible state, why targeting the biology of ageing itself may matter more than tackling diseases one at a time, and what meaningful rejuvenation should really look like.
Prof Lorna also discusses the challenge of turning lab science into therapies through her spin-out SENISCA, her work with L’Oréal, and why conditions such as IPF are an important place to begin. Along the way, she addresses the tougher questions too, including how longevity science moves from promise to treatment, where the field risks drifting into hype, and whether these advances will be available to the many or only the few.
Links:
http://www.senisca/
http://www.iscarna.com/
https://teamrna.wixsite.com/harrieslab
https://experts.exeter.ac.uk/1873-lorna-harries
Innovate UK ICURe Programme
https://iuk-business-connect.org.uk/programme/icure/
00:00 Podcast Intro Guest Setup
01:50 Meet Professor Harris Basics
02:16 DNA RNA Explained
03:38 RNA Splicing And Ageing
05:48 What Senescent Cells Do
07:38 Reversing Senescence Window
09:01 Fat Tissue And Faster Ageing
11:01 Splicing As Central Hallmark
12:11 Rejuvenation Discovery Story
13:52 From Lab To Spinout Company
16:41 Translating Science To Products
19:17 Therapy Targets IPF And Beyond
21:45 Why Translation Often Fails
23:19 Defining Real Rejuvenation
25:14 Avoiding Hype In Longevity
27:17 Who Is Lagging Behind
27:37 Regulatory Mindset Shift
28:47 Trials Built for Ageing
29:28 Scepticism and Overhype
31:25 Is Ageing a Disease
32:49 Policy and Demographic Timebomb
33:48 Advocacy and Communication
35:24 Personal Ageing Habits
36:24 Key Unasked Questions
39:15 Longevity for the Rich
41:43 Access via NHS and Patents
45:06 Rapid Fire and Myths
49:05 Closing Reflections
Recorded at the 2026 VIVE conference in Los Angeles, this Beyond Longevity mini-series episode features Mark Zemel, co-founder and CEO of Retia Medical, discussing the company’s hemodynamic monitoring technology that turns continuous bedside physiological signals into real-time clinical insights for high-risk surgery and critical care.
Marc explains Retia’s aim to detect early deterioration, guide diagnosis and therapy, and avoid the unreliability, invasiveness and complexity of older tools, noting deployment in 75 US hospitals and distribution via Medtronic, plus presence in 18 countries.
He highlights FDA clearance for Argos Infinity enterprise software, which extends insights across the hospital and to clinicians’ phones and laptops, and shares a case where rapid detection of falling stroke volume revealed bleeding during AAA repair. The conversation covers workflow-first design, interoperability, cybersecurity, regulatory strategy, and a future path from ICU to broader wards and ultimately wearables for earlier intervention and preventative care.
00:00 Beyond Longevity Intro
00:44 Meet Mark Zeel
01:40 Rata Medical Mission
02:54 Argos Infinity Launch
03:58 Clinicians Want Real Time
05:19 Surgery Near Miss Story
07:20 Why Accuracy Matters
08:42 Why Algorithms Are Hard
10:08 From ICU To Wearables
12:20 Scaling Distribution Globally
13:22 Plug And Play Integration
15:22 Wearables And Data Overload
18:31 Alerts And Clinical Judgment
20:16 AI As Decision Support
21:56 US Versus Europe Markets
23:09 Wearables Beyond EMRs
23:57 Regulation And Cybersecurity
25:07 FDA And AI Pathways
26:50 Clinician Workflow Design
29:39 Bad Data From Friction
31:58 Open Ecosystems Future
33:25 Prevention And Longevity
35:46 Personal Why Wearables Matter
39:24 From ICU To Early Detection
41:44 Rapid Fire And Wrap
This week’s guest is Avivah Wittenberg-Cox. Avivah advises leaders on gender and generational balance, the future of work, and the longevity economy. She hosts the podcast 4-Quarter Lives, publishes the Substack Elderberries, and writes regularly for Forbes and Harvard Business Review. She is Visiting Faculty at Oxford’s Saïd Business School, co-directs the Longevity Leadership Programme at Católica Lisbon, and has given three TED Talks.
In this episode, Avivah and Daphna explore how longer lives are reshaping work, business, and society. Avivah argues that longevity is not just a health story but a structural shift that is forcing organisations to rethink how they are built, how careers unfold, and how different generations work together.
She explains why the old pyramid model of the workforce is giving way to a more square demographic reality, with far more balance between younger and older generations than most institutions were designed for. That shift brings real pressure, from pensions to healthcare, but also major opportunities for businesses willing to adapt.
The conversation looks at why older workers are still too often overlooked, what businesses lose when they fail to value experience, and why age-inclusive thinking is becoming a strategic advantage rather than a social add-on. More broadly, the episode challenges outdated assumptions about ageing and asks what it would mean to build a society that treats longer lives as a source of possibility, not decline.
This episode is a reminder that longevity is not only changing how long we live, but how we work, lead, learn, and contribute across the course of our lives.
https://www.avivahwittenbergcox.com/
https://elderberries.substack.com
https://elderberries.substack.com/podcast
https://www.ted.com/search?q=Avivah+Wittenberg+Cox
https://20-first.com/
https://www.forbes.com/sites/avivahwittenbergcox/#61c5a38ebf19
00:00 Longevity Meets Work
02:06 Longevity Mega Trend
03:09 Institutions Lag Behind
05:37 From Gender To Age
07:39 Women And Longer Lives
10:08 Multi Stage Careers
11:26 Rethinking Education Midlife
15:29 Rebranding Old Age
17:54 Opportunity And Ageism
21:24 Fear Of Ageing And Happiness
25:37 Goldman Sachs And AI
27:17 Company First Mover Advantage
28:43 Who Is Leading The Way
29:52 Brands Embrace Pro Ageing
30:21 Longevity In Hospitality
31:12 Retirees As Consultants
31:56 Why Leaders Miss Demographics
35:29 Government Levers And Limits
38:34 The Square Society Shift
40:43 Measuring Longevity Readiness
43:25 Advice Four Quarter Lives
47:54 Designing A Four Quarter Life
53:22 Ageing Better Than Expected
54:46 Rapid Fire And Wrap Up
In this episode, Dr Jin-Xiong She, a scientist with more than 400 publications, over 20,000 citations, and more than $100 million in research funding, explains why he left the top tier of academic medicine to pursue something more urgent: finding better ways to detect decline early and protect healthspan before disease takes hold. He shares what nearly 100,000 NAD tests have uncovered and why he believes biomarker baselines could change the way we think about prevention.
https://www.jinfiniti.com/
https://www.youtube.com/@ProfJinShe
In this episode:
00:00 Welcome and Guest Intro
01:47 From Genomics to Longevity
04:18 T1D TEDDY Study Breakthroughs
06:07 Leaving Academia for Impact
07:37 Healthspan Over Lifespan
10:09 TAO Test Act Optimise
13:20 Choosing Actionable Biomarkers
17:02 Why NAD Tops the List
21:45 NAD Decline and Key Drivers
25:21 Raising NAD Lifestyle vs Supplements
27:51 Athletes' Inflammation and Low NAD
31:54 Optimal NAD Range and Niacin Risks
37:28 SubQ Injections vs Oral NMN Data
41:42 Dosing and Cutting Useless Supplements
43:52 Access Economics and Policy Ideas
46:50 Industry Adoption and Big Names
47:59 Supplement Market Problems
50:17 Rapid Fire and Closing Takeaways
52:04 Final Summary and Goodbye
What does it take to turn longevity science into real-world policy? In this episode, Daphna speaks with Dr Ilia Stambler, historian of longevity, published author, Chair of the International Longevity Alliance (ILA), and Chief Science Officer and Chairman of Vetek (Seniority) Association, about why advocacy and ecosystem-building may be just as important as the science itself.
Dr Stambler shares how the ILA has grown into a global network connecting 76 nonprofits across 66 countries, organising international conferences, and running the annual Longevity Day (1st October) and Longevity Month (October) campaigns. He points to concrete wins, including efforts to support the inclusion of ageing-related conditions in the ICD and the WHO's work programme.
The conversation gets honest about the real barriers to progress. Dr Stambler argues the problem isn't convincing governments that ageing matters, it's getting them to treat it with urgency. Despite ageing representing one of the largest disease burdens globally, it remains chronically underfunded and deprioritised, in part because the research timelines required don't fit neatly into political cycles.
He also reflects on the deeper intellectual questions underpinning the field: how to balance holism and reductionism, why historical perspective is essential for longevity researchers, and how the same patterns of enthusiasm, scepticism, and neglect have repeated across centuries of rejuvenation science.
Looking ahead to 2030, Dr Stambler highlights the need for better public education, evidence-based criteria for evaluating interventions, and growing grassroots motivation, because ultimately, he believes, a longer and healthier life begins with wanting one.
In This Episode:
Ilia Stambler, PhD
Chairman and CSO. Vetek (Seniority) Association – The Movement for Longevity and Quality of Life, Israel http://www.longevityisrael.org/
Chairman. International Longevity Alliance (ILA) http://www.longevityalliance.org/
Fellow. Department of Science, Technology and Society, Bar-Ilan University, Israel https://sts.biu.ac.il/
Author. A History of Life-Extensionism in the Twentieth Century; Longevity Promotion: Multidisciplinary Perspectives; Healthy Longevity: Policies and Practices http://longevityhistory.com
https://www.longevityhistory.com/about-the-author/
00:00 Welcome and Guest Intro
01:28 Staler Background and Mission
03:18 What the ILA Does
04:04 Key Wins and Campaigns
05:25 Public Misconceptions
07:27 Getting Governments to Act
09:14 Funding Research Long Term
10:49 Education and Conferences
12:05 Which Countries Lead
15:22 Why Advocacy Beats Solo Science
17:38 Advocacy Success Stories
20:48 Breaking Longevity Silos
21:23 Holism vs Reductionism
22:28 Why History Matters
24:17 Death Valley of Ideas
25:49 Rejuvenation Patterns Repeat
27:42 Misunderstood Longevity History
29:22 Balance and Modesty
31:23 Measuring Real Success
34:59 Making Longevity Policy
36:09 Rapid Fire Takeaways
38:58 Final Wrap Up
In this episode, Daphna sits down with Elio, co-founder of LongevAI, a platform using artificial intelligence to help longevity clinics analyse biomarker data, streamline documentation, and build personalised client plans.
With a background in computer science and a lifelong passion for health optimisation, Elio offers a grounded, honest perspective on what AI in longevity medicine can do today, and where the limits still lie.
______________
What We Cover
• How LongevAI was founded and what problem it solves for longevity clinics
• What it means to automate clinical documentation without removing the clinician from the process
• How AI interprets biomarker data, and why speed and accuracy both play a role
• The hallucination problem: what it is, why it happens, and how it is being managed
• Data privacy, GDPR compliance, and anonymisation in clinical AI tools
• The importance of human oversight, why the clinician must always approve before anything reaches the client
• How AI and clinicians can learn from each other in a feedback loop
• Wearable integration and the role of continuous vs snapshot data
• Where AI in longevity is heading in two to five years, including gene therapy modelling and whole-cell simulation
• Why younger people are beginning to engage with longevity, and what still holds them back
About the Guest
Elio is the co-founder of LongevAI, a software platform built for longevity clinics. He holds a double bachelor's degree in Computer Science and Information Science, and has been focused on health optimisation and AI since his teens. He co-founded LongevAI in December 2024 alongside Cosmina Druica, whom he met through a longevity meetup community in the Netherlands.
🔗 longevai.com
Enjoyed this episode? Please subscribe, leave a review on Apple Podcasts or Spotify, and share with anyone curious about the future of longevity medicine.
Beyond Longevity is hosted by Daphna Stern · beyond-longevity.co.uk
In this episode:
00:00 Welcome and Guest Intro
01:52 Elio Background and Origins
04:01 What Lev AI Does
05:06 Automating Clinic Workflows
07:52 Speed vs Accuracy
11:45 Oversight and Patient Trust
12:57 Privacy and GDPR Security
13:56 How the Model Improves
15:06 Limits Data and Hallucinations
21:37 Training and Integrations
23:45 Personal Biomarker Walkthrough
28:34 Explaining LLMs to non-tech people
33:38 Future of AI and Longevity
35:32 Young People and Longevity
39:56 Rapid Fire Questions
43:45 Wrap Up and Key Takeaways
Dr Bradley Elliott — physiologist, university lecturer, and a trustee and Communications Lead at the British Society for Research on Ageing — joins host Daphna for a refreshingly honest conversation about what longevity science actually knows and what we still cannot explain.
This episode cuts through the certainty. We talk about biomarkers and biological age, why many measurements may be tracking effects rather than causes, we discuss extracellular vesicles and the surprising limit of science. Dr Bradley discusses some of his papers and related research, and our conversation challenges much of the conventional wisdom in the longevity space.
What we cover:
-Why we still do not know what fundamentally causes ageing — and why every “root cause” often leads to something deeper
-What biomarkers really measure, what they can and cannot tell you, and which markers are most worth tracking right now
-Biological age vs chronological age: where the concept is useful, and where it gets overclaimed
-Why muscle is one of the most underrated “health organs” in ageing — and what it supports beyond strength
-Exercise for longevity: the evidence-based basics, plus what matters most for consistency and adherence
-“It is not too late”: what studies in very old adults suggest about strength gains later in life
-Extracellular vesicles: the hidden communication system between cells, and why it is getting so much attention
-Wearables: why they can still be useful even when the numbers are not perfectly accurate
This is a fascinating episode with someone who knows how to communicate science and make it relatable
Links to Dr Bradley Elliot:
- https://www.westminster.ac.uk/about-us/our-people/directory/elliott-bradley
- https://bsra.org.uk/bradley-elliott-2/
- https://www.bradelliott.online/
Papers & Research Referenced• Perri et al. (2025) — Delphi review identifying 14 biomarkers of ageing for use in human research (co-authored by Dr Elliott)
' https://pubmed.ncbi.nlm.nih.gov/39708300/
• Lady V Barrios-Silva et al. — Activin subfamily peptides and prediction of age and physical function (undergraduate-led research, University of Westminster)
https://pubmed.ncbi.nlm.nih.gov/30178598/
• Dr Yvoni Kyriakidou (PhD) — Exercise-induced muscle damage in young and old men; extracellular vesicle characterisation post-exercise
https://pubmed.ncbi.nlm.nih.gov/34650440/
• Dr Niharika Duggal (University of Birmingham) — Masters athletes and immune function; older athletes vs. age-matched non-athletes
https://pubmed.ncbi.nlm.nih.gov/29517845/
• Stephen Harridge (King's College London) — Resistance training in 90+ year olds; gains in muscle strength and mass in the oldest old
https://pubmed.ncbi.nlm.nih.gov/10398199/
• Science paper on genetic contribution to longevity — updated estimate shifting genetic contribution to ~50% (noted with editorial by Dr Elliott)
https://www.science.org/doi/10.1126/science.adz1187
https://theconversation.com/what-new-twins-study-reveals-about-genes-environment-and-longevity-274763
https://www.ukbiobank.ac.uk/
If you enjoyed this episode, we'd love it if you took 60 seconds to leave us a review on Apple Podcasts or Spotify. It genuinely helps more people find the show and means we can keep bringing you honest, science-backed conversations like this one. Thank you
https://beyond-longevity.co.uk/
Chapters:
00:00 Why We Age
01:52 Meet Bradley Elliot
03:07 From Sports Science
05:32 Defining Ageing
07:03 Mechanisms And Theories
09:29 Biomarkers Explained
13:02 Delphi Biomarker List
16:59 Myostatin Study Story
21:25 Actionable Biomarkers
26:07 Wearables And Accuracy
27:38 Endocrine Fingerprints
30:11 Muscle And Healthy Ageing
33:21 Athletes And Immunity
34:26 Muscle Mass And Healthspan
36:36 Exercise Dose Guidelines
39:42 Resistance Training Plateau
40:42 Lifestyle Versus Genetics
42:42 Muscle Damage Study
44:44 Extracellular Vesicles Explained
46:49 Young Blood Controversy
50:08 Dream Research With Omics
56:55 What People Misjudge
58:43 It’s Never Too Late
01:02:41 Rapid Fire And Wrap
01:04:31 Final Takeaways
In this episode, I sit down with Dr Brendan Khong, a London-based aesthetic physician and regenerative medicine advocate, for a practical conversation about what it really means to age well, starting with the skin, but quickly expanding into whole-body biology.
The central theme is a shift now reshaping aesthetic medicine: moving away from surface-level fixes and toward addressing the underlying drivers of visible ageing. A key driver, Dr Brendan explains, is inflammaging, a chronic, low-grade inflammation that builds over time and accelerates both skin ageing and broader physiological decline.
He breaks down why some conventional aesthetic approaches can backfire, particularly repeated high-heat energy treatments, which may contribute to fibrosis, uneven pigmentation, and a dull, “waxy” skin texture over time. His approach favours smarter, gentler interventions, including an anti-inflammatory 1064nm Nd:YAG laser, targeted resurfacing that can be safer across a wider range of skin types, and calming injectables such as Meso-Wharton (a peptide product derived from Wharton’s jelly) used in practice to support skin quality, texture and fine lines.
But this is not just a conversation about devices and injectables. Dr Brendan argues that better results start with better assessment and the need to factor in gut health, supplement use, stress load, and cortisol patterns before reaching for a needle or a laser. He is also candid about timelines: collagen remodelling takes time, and unrealistic expectations are one of the biggest problems in aesthetics.
For day-to-day longevity habits that support skin health, he highlights fundamentals that are often overlooked: exercise, stress management, avoiding very hot showers, and finding a retinoid your skin can consistently tolerate.
Dr Brendan Khong | London's Most Sought-after Aesthetic Doctor
Dr Brendan Khong (@drbrendankhong) • Instagram profile
00:00 Welcome and Guest Intro
02:06 Brandon’s Medical Journey
03:36 Skin as an Inflammation Mirror
07:19 Supplements and Gut Health
10:15 Overtreatment and Inflammaging
14:47 Anti-Inflammatory Laser Approach
17:39 Regenerative Injectables Peptides
21:36 Personalised Protocols and Expectations
25:18 Why Glanine Stands Out
25:57 Microspheres Not Clumps
26:55 Anti-Inflammatory Collagen
27:47 Safety Profile Focus
28:45 Building Patient Protocols
30:25 Longevity Over Quick Fixes
32:17 Future Of Aesthetics
33:41 Gentler Treatment Philosophy
34:49 Quantum Magnetic Resonance
36:18 Healthy Beauty Trends
37:25 Daily Longevity Skin Tips
40:10 Rapid Fire Longevity Qs
45:14 Final Takeaways And Wrap
From the publisher's feed